Steve H Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steve H Kim has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Jin K Choe
Pathology and Laboratory Medicine Services, VA New Jersey Healthcare System, 385 Tremont Avenue, East Orange, New Jersey, NJ 07018, USA
1 shared publication- Kim Bowers
Department of Surgery, New Jersey Medical School, University of Medicine and Dentistry, Newark, New Jersey, USA
1 shared publication Michael B Mathews
Department of Biochemistry and Molecular Biology, New Jersey Medical School/University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, Newark, New Jersey, NJ 07103, USA
1 shared publication- Nasrin Ghesani
Department of Radiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, UH H 141 Newark, NJ 07103, USA
1 shared publication Shobha Gunnery
Department of Biochemistry and Molecular Biology, New Jersey Medical School/University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, Newark, New Jersey, NJ 07103, USA
1 shared publication- Yiyan Liu
Department of Radiology, Nuclear Medicine Service, University Hospital, UMDNJ, Newark, NJ 07103, USA
1 shared publication
Latest Publications
- Open Access
- 7 June 2006
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 4 (1) , 31
A level III sentinel lymph node in breast cancer
Background: For accurate nodal staging, all blue and radioactive lymph nodes should be sampled during the sentinel lymph node biopsy for breast cancer. We report a case of anomalous drainage in which one of the sentinel lymph nodes was unexpectedly found in the level III axillary space. Case presentation: A 40-year-old female underwent mastectomy for extensive high-grade ductal carcinoma in-situ (DCIS) with micro-invasion. The index lesion was located in the right upper inner quadrant. Lymphoscintigraphy was performed on the morning of surgery. Two sentinel lymph nodes were identified. At operation, 5 mls of isosulfan blue dye was injected at the same site of the radio-colloid injection. The first sentinel lymph node was found at level I and was blue and radioactive. The second sentinel node was detected in an unexpected anomalous location at level III, medial to the pectoralis minor. Both sentinel nodes were negative. Conclusion: Sentinel node staging can lead to unexpected patterns of lymphatic drainage. For accurate staging, it is important to survey all potential sites of nodal metastasis either with preoperative lymphoscintigraphy and/or rigorous examination of regional nodal basins with the intra-operative gamma probe.
- 7 June 2006
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 4 (1) , 31
Open AccessA level III sentinel lymph node in breast cancer
Background: For accurate nodal staging, all blue and radioactive lymph nodes should be sampled during the sentinel lymph node biopsy for breast cancer. We report a case of anomalous drainage in which one of the sentinel lymph nodes was unexpectedly found in the level III axillary space. Case presentation: A 40-year-old female underwent mastectomy for extensive high-grade ductal carcinoma in-situ (DCIS) with micro-invasion. The index lesion was located in the right upper inner quadrant. Lymphoscintigraphy was performed on the morning of surgery. Two sentinel lymph nodes were identified. At operation, 5 mls of isosulfan blue dye was injected at the same site of the radio-colloid injection. The first sentinel lymph node was found at level I and was blue and radioactive. The second sentinel node was detected in an unexpected anomalous location at level III, medial to the pectoralis minor. Both sentinel nodes were negative. Conclusion: Sentinel node staging can lead to unexpected patterns of lymphatic drainage. For accurate staging, it is important to survey all potential sites of nodal metastasis either with preoperative lymphoscintigraphy and/or rigorous examination of regional nodal basins with the intra-operative gamma probe.
- 12 December 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (57) , 8741-8748
Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR
The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2α, and the transcription factor, NF-κB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2α in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-α2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.
- 12 December 2002
- Published by Springer Nature in Oncogene
- Vol. 21 (57) , 8741-8748
Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR
The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2α, and the transcription factor, NF-κB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2α in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-α2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.